Nieder Carsten, Dalhaug Astrid, Pawinski Adam
Department of Oncology and Palliative Medicine, Nordland Hospital, Bodø, Norway
Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
In Vivo. 2019 Jan-Feb;33(1):229-232. doi: 10.21873/invivo.11464.
BACKGROUND/AIM: The aim of this study was to analyze the prognostic impact of serum lactate dehydrogenase (LDH) in patients with oligometastatic brain metastases, arbitrarily defined as max. Four brain lesions and 5 metastatic lesions overall.
This was a retrospective single institution analysis. Overall, 42 patients were identified from a prospectively maintained database.
Seventeen patients (40%) had extracranial metastases. Twelve patients (29%) had elevated LDH (≥255 U/l). Their median survival was significantly shorter than that of patients with normal LDH. Due to an interaction with performance status, this result was separately confirmed in patients with performance status ≥70.
Oligometastatic disease is not always correctly diagnosed, because all radiological modalities are limited by certain thresholds for detection of small metastases. We hypothesize that LDH is associated with survival, because this biomarker may reflect the total burden of malignant disease. Future studies should examine whether or not ablative local treatment of oligometastases is warranted in patients with elevated LDH.
背景/目的：本研究旨在分析血清乳酸脱氢酶（LDH）对寡转移性脑转移瘤患者的预后影响，寡转移性脑转移瘤被任意定义为最多4个脑转移灶且全身转移灶总数为5个。
这是一项单机构回顾性分析。总体而言，从一个前瞻性维护的数据库中识别出42例患者。
17例患者（40%）有颅外转移。12例患者（29%）LDH升高（≥255 U/l）。他们的中位生存期明显短于LDH正常的患者。由于与体能状态存在相互作用，该结果在体能状态≥70的患者中得到了单独证实。
寡转移性疾病并非总能被正确诊断，因为所有影像学检查方法都受小转移灶检测的某些阈值限制。我们推测LDH与生存期相关，因为这种生物标志物可能反映恶性疾病的总体负担。未来研究应探讨对于LDH升高的患者，是否有必要对寡转移灶进行局部消融治疗。
